Europe’s disease control agency has cautioned against the leverage of doxycycline as a preventative measure against sexually transmitted infections (STIs), citing concerns over increasing antibiotic resistance. The European Centre for Disease Prevention and Control (ECDC) issued its recommendation following a rise in cases of gonorrhea exhibiting resistance to the antibiotic, according to Medscape.
The preventative use of doxycycline, known as doxycycline post-exposure prophylaxis (DoxyPEP), gained traction in recent years as a tool to combat the spread of STIs, particularly among men who have sex with men. The Centers for Disease Control and Prevention (CDC) in the United States has likewise provided guidance on DoxyPEP, outlining its use after potential exposure to chlamydia, gonorrhea, or syphilis. However, the ECDC’s warning highlights a growing tension between public health strategies and the potential for accelerating antimicrobial resistance.
Researchers at the Harvard T.H. Chan School of Public Health suggest a link between the widespread use of doxycycline for STI prevention and the emergence of antibiotic-resistant gonorrhea. The concern is that frequent, low-dose exposure to the antibiotic creates conditions that favor the development of resistance mechanisms in the bacteria. Gonorrhea is already considered a significant public health threat due to its increasing resistance to multiple antibiotics.
The ECDC’s recommendation specifically advises against offering doxycycline for STI prevention, emphasizing the need to preserve the effectiveness of the antibiotic for treating existing infections. This stance contrasts with some public health approaches that have embraced DoxyPEP as a proactive measure to reduce STI incidence. The European AIDS Treatment Group has also reported on the issue, noting the link between the preventative use of the drug and antibiotic resistance.
The implications of the ECDC’s guidance are still unfolding, and it remains to be seen how national health authorities across Europe will respond. The CDC has not yet issued a revised statement regarding DoxyPEP in light of the ECDC’s recommendation, and continues to offer guidance on its use. Further research is needed to fully understand the long-term consequences of widespread doxycycline use for STI prevention and to develop alternative strategies for controlling the spread of these infections.
